Electric pulses plus immunotherapy take on tough pancreatic cancer
NCT ID NCT03080974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to treat advanced pancreatic cancer by combining two approaches: a drug called nivolumab that helps the immune system fight cancer, and a procedure called irreversible electroporation that uses electric pulses to destroy tumor cells. The goal is to see if this combination is safe and can help people live longer. The study is for 10 adults with stage III pancreatic cancer whose tumor can be measured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors